Advertisement
MESO vs SPRY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MESO is a Hold and SPRY is a Hold.
MESO sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for MESO moved below the 200-day moving average on September 24, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MESO as a result. In 78 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
MESO moved below its 50-day moving average on September 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MESO crossed bearishly below the 50-day moving average on September 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MESO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for MESO entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MESO's RSI Oscillator exited the oversold zone, 19 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 63 cases where MESO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
Following a +5.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where MESO advanced for three days, in 240 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
MESO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. MESO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 92 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MESO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.312) is normal, around the industry mean (26.782). P/E Ratio (0.122) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (29.240) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (15.504) is also within normal values, averaging (437.542).
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
SPRY in -5.98% downward trend, sliding for three consecutive days on October 14, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SPRY declined for three days, in 231 of 269 cases, the price declined further within the following month. The odds of a continued downward trend are 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SPRY as a result. In 74 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Aroon Indicator for SPRY entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SPRY's RSI Indicator exited the oversold zone, 29 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for SPRY just turned positive on September 29, 2026. Looking at past instances where SPRY's MACD turned positive, the stock continued to rise in 44 of 50 cases over the following month. The odds of a continued upward trend are 88%.
Following a +6.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where SPRY advanced for three days, in 233 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SPRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. SPRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (32.787) is normal, around the industry mean (26.782). P/E Ratio (151.250) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (3.535) is also within normal values, averaging (437.542).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SPRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
MESO | SPRY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 67 | 6 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 93 Overvalued | 95 Overvalued | |
PROFIT vs RISK RATING 1..100 | 92 | 100 | |
SMR RATING 1..100 | 94 | 100 | |
PRICE GROWTH RATING 1..100 | 76 | 89 | |
P/E GROWTH RATING 1..100 | 96 | 58 | |
SEASONALITY SCORE 1..100 | 39 | 9 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MESO's Valuation (93) in the Biotechnology industry is in the same range as SPRY (95) in the null industry. This means that MESO’s stock grew similarly to SPRY’s over the last 12 months.
MESO's Profit vs Risk Rating (92) in the Biotechnology industry is in the same range as SPRY (100) in the null industry. This means that MESO’s stock grew similarly to SPRY’s over the last 12 months.
MESO's SMR Rating (94) in the Biotechnology industry is in the same range as SPRY (100) in the null industry. This means that MESO’s stock grew similarly to SPRY’s over the last 12 months.
MESO's Price Growth Rating (76) in the Biotechnology industry is in the same range as SPRY (89) in the null industry. This means that MESO’s stock grew similarly to SPRY’s over the last 12 months.
SPRY's P/E Growth Rating (58) in the null industry is somewhat better than the same rating for MESO (96) in the Biotechnology industry. This means that SPRY’s stock grew somewhat faster than MESO’s over the last 12 months.
| MESO | SPRY | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 76% | 1 day ago 85% |
| Stochastic ODDS (%) | 1 day ago 73% | 1 day ago 79% |
| Momentum ODDS (%) | 1 day ago 83% | 1 day ago 81% |
| MACD ODDS (%) | N/A | 1 day ago 88% |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 85% |
| TrendMonth ODDS (%) | 1 day ago 79% | 1 day ago 84% |
| Advances ODDS (%) | 24 days ago 84% | 8 days ago 82% |
| Declines ODDS (%) | 1 day ago 83% | 1 day ago 86% |
| BollingerBands ODDS (%) | 4 days ago 70% | 3 days ago 77% |
| Aroon ODDS (%) | 1 day ago 85% | 1 day ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MESO’s FA Score shows that 0 FA rating(s) are green while SPRY’s FA Score has 0 green FA rating(s).
- MESO’s FA Score: 0 green, 5 red.
- SPRY’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MESO’s TA Score shows that 4 TA indicator(s) are bullish while SPRY’s TA Score has 5 bullish TA indicator(s).
- MESO’s TA Score: 4 bullish, 6 bearish.
- SPRY’s TA Score: 5 bullish, 3 bearish.
Price Growth
MESO (@Biotechnology) experienced а -1.08% price change this week, while SPRY (@Biotechnology) price change was -9.86% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.52%. For the same industry, the average monthly price growth was -19.04%, and the average quarterly price growth was -19.99%.
Reported Earning Dates
MESO is expected to report earnings on Nov 25, 2026.
SPRY is expected to report earnings on Nov 17, 2026.
Industries' Descriptions
@Biotechnology (-8.52% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement